Regeneron Pharmaceuticals
REGN
$762.63
+3.29%
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes medicines for eye disease, cardiovascular disease, cancer, and inflammation, with key products including Eylea, Dupixent, and Libtayo. It is a leading innovator in the biotech space, known for its robust R&D engine and strategic partnerships with Sanofi and Bayer. The current investor narrative centers on the company's growth trajectory following a Phase 3 clinical trial failure for a key cancer drug combination in May 2026, which triggered a sharp sell-off and raised questions about pipeline depth, though strong Dupixent sales and a favorable analyst outlook provide a counterbalance.…
REGN
Regeneron Pharmaceuticals
$762.63
Related headlines
Investment Opinion: Should I buy REGN Today?
Rating: Buy. Thesis: Regeneron offers a rare combination of double-digit revenue growth, a fortress balance sheet, and a discounted valuation, making it an attractive value play in biotech despite recent pipeline setbacks. The analyst consensus is Buy with a mean target of $819.25, implying 24.9% upside.
Supporting Evidence: Revenue grew 19.0% YoY in Q1 2026, accelerating from prior quarters. The trailing P/E of 17.9x is below the biotech industry average of 22x, and the forward P/E of 12.0x suggests earnings growth is expected. Free cash flow of $4.16B TTM provides a 5.2% FCF yield, and the company has a net cash position with debt-to-equity of only 0.087. The ROE of 14.4% indicates efficient capital use, and the company returns capital via buybacks and a small dividend.
Risks & Conditions: The biggest risks are further pipeline failures, margin compression from rising R&D, and competitive pressure on Eylea. This Buy rating would be downgraded to Hold if the forward P/E exceeds 18x or if revenue growth decelerates below 10%. It would be upgraded to Strong Buy if the stock pulls back to $600 or if a major pipeline success is announced. Overall, REGN appears undervalued relative to its history and peers, offering a favorable risk/reward for long-term investors.
Sign up to view all
REGN 12-Month Price Forecast
Regeneron's strong revenue growth, fortress balance sheet, and discounted valuation make it an attractive investment, but the recent pipeline setback and margin compression warrant caution. The base case of steady growth and gradual margin recovery is most likely, supported by analyst optimism. However, the stock's technical downtrend and high uncertainty around pipeline outcomes limit confidence. A bullish stance is justified by the valuation discount and fundamental strength, but investors should monitor upcoming clinical data and earnings for signs of a catalyst. An upgrade to high confidence would require a positive pipeline catalyst or sustained margin improvement.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $823.35 and implied upside of +8.0% versus the current price.
Average Target
$823.35
0 analysts
Implied Upside
+8.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$641 - $1000
Analyst target range
Regeneron is covered by 26 analysts, with a consensus recommendation of 'Buy' (mean rating 1.81 on a 1-5 scale). The average target price is $819.25, implying a substantial 24.9% upside from the current price of $656.01. The distribution leans heavily bullish, with recent upgrades from Benchmark (Hold to Buy) and reaffirmations from Piper Sandler, Cantor Fitzgerald, and HSBC. The high target of $1,000 suggests some analysts see significant upside from pipeline success or multiple expansion, while the low target of $641.00 is slightly below the current price, indicating downside risk if pipeline setbacks persist. The wide spread between low and high ($359) reflects high uncertainty around pipeline outcomes and competitive dynamics. Recent downgrades include Leerink Partners (Outperform to Market Perform) and a hold from Morgan Stanley, indicating some caution. Overall, the consensus is bullish but with notable dispersion, implying that investors should weigh the potential for a strong recovery against the risk of further pipeline disappointments.
Drowning in data?
Find the real signal!
Bulls vs Bears: REGN Investment Factors
Regeneron presents a compelling value opportunity with strong revenue growth, a fortress balance sheet, and a discounted valuation relative to peers. However, the recent Phase 3 failure has cast doubt on pipeline vitality, leading to margin compression and negative momentum. The bull case rests on the company's ability to deliver on existing products and advance its pipeline, while the bear case centers on further clinical setbacks and competitive pressures. The single most important tension is whether the pipeline can recover from the May 2026 setback; if it does, the stock could re-rate significantly, but if further failures emerge, downside to the 52-week low of $541 is possible. Currently, the evidence slightly favors the bulls due to strong fundamentals and analyst support, but caution is warranted given the technical downtrend.
Bullish
- Strong Revenue Growth: Revenue grew 19.0% YoY in Q1 2026 to $3.605B, accelerating from 18.9% in Q4 2025, driven by Dupixent and Eylea. TTM revenue is ~$14.8B, indicating robust top-line momentum.
- Attractive Valuation Discount: Trailing P/E of 17.9x is a 19% discount to the biotech industry average of ~22x, and forward P/E of 12.0x is a 45% discount. This low multiple relative to history and peers suggests undervaluation.
- Strong Free Cash Flow Generation: TTM free cash flow is $4.16B, providing ample liquidity for R&D investment, buybacks ($794M in Q1), and debt reduction. FCF yield is ~5.2%, attractive for value investors.
- Fortress Balance Sheet: Debt-to-equity is only 0.087, and current ratio is 4.13, indicating minimal leverage and strong liquidity. This financial stability reduces bankruptcy risk and supports capital returns.
Bearish
- Pipeline Setback in Oncology: A Phase 3 trial failure for a key cancer drug combination in May 2026 triggered a sharp sell-off, with the stock dropping ~15% in a single day. This raises doubts about pipeline depth and future growth drivers.
- Margin Compression: Operating margin fell to 17.8% in Q1 2026 from 27.3% in Q3 2025, due to higher R&D spending ($1.645B, up 23% YoY). Net margin also declined to 20.2% from 38.9%, pressuring earnings.
- High Valuation Uncertainty: PEG ratio of 3.38 suggests the stock is expensive relative to its growth rate. The wide spread between analyst low ($641) and high ($1,000) targets reflects high uncertainty around pipeline outcomes.
- Negative Relative Strength: REGN has underperformed the S&P 500 by 16.2% over 3 months and 20.2% over 6 months. The stock is in a clear downtrend, trading near 80% of its 52-week range, indicating persistent bearish sentiment.
REGN Technical Analysis
Regeneron is in a clear downtrend over the past year, with the stock declining 16.2% from its 52-week high of $821.11 to a current price of $656.01, trading at approximately 80% of its 52-week range. This positioning near the lower end of the range suggests bearish sentiment and potential value opportunity, but also reflects the market's negative reaction to recent pipeline setbacks. The 1-year price change of +16.2% masks significant intra-year volatility, as the stock has fallen sharply from its highs. Short-term momentum shows a conflicting picture: the 1-month price change is +5.2%, indicating a recent bounce, while the 3-month change is -12.7%, highlighting the severity of the May sell-off. This divergence suggests a potential short-term recovery attempt within a broader downtrend, but the 6-month change of -12.9% confirms persistent weakness. The RSI is not provided, but the sharp decline and subsequent stabilization could indicate oversold conditions. The 52-week low of $541.00 serves as critical support, while the 52-week high of $821.11 is a major resistance level. A breakout above $821 would signal a reversal of the downtrend, while a breakdown below $541 could accelerate selling. Beta is 0.236, indicating the stock is significantly less volatile than the market, which is unusual for a biotech and may reflect its large-cap status and diversified revenue base; this low beta implies that the stock's movements are less driven by broad market swings and more by company-specific catalysts.
Beta
0.24
0.24x market volatility
Max Drawdown
-26.1%
Largest decline past year
52-Week Range
$541-$821
Price range past year
Annual Return
+39.8%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | +22.1% | +0.2% |
| 3m | +8.7% | +3.7% |
| 6m | +2.9% | +8.0% |
| 1y | +39.8% | +18.2% |
| ytd | -1.8% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Revenue growth remains robust, with Q1 2026 revenue of $3.605 billion up 19.0% year-over-year, accelerating from the 18.9% growth in Q4 2025 and 21.4% in Q3 2025. The trailing twelve-month revenue is approximately $14.8 billion, driven by strong collaboration revenue ($1.9 billion in Q1) and product sales ($1.53 billion), with Dupixent and Eylea as key growth drivers. The multi-quarter trend shows consistent double-digit growth, though the pace has moderated slightly from the 2021-2022 pandemic highs. Profitability is solid, with net income of $727 million in Q1 2026 and a net margin of 20.2%, down from 38.9% in Q3 2025 due to higher R&D spending and a one-time charge. Gross margin remains high at 85.4%, typical for biotech, but operating margin compressed to 17.8% from 27.3% in Q3 2025, reflecting increased investment in pipeline programs. The company is profitable and generates substantial cash, with free cash flow of $848 million in Q1 2026 and $4.16 billion over the trailing twelve months. The balance sheet is fortress-like: debt-to-equity is just 0.087, and the current ratio is 4.13, indicating ample liquidity. ROE is 14.4%, reflecting efficient capital use, and the company returns capital to shareholders via buybacks ($794 million in Q1) and a small dividend (yield 0.46%).
Quarterly Revenue
$3.6B
2026-03
Revenue YoY Growth
+19.0%
YoY Comparison
Gross Margin
81.4%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 17.9x, while the forward P/E is 12.0x, implying the market expects earnings growth to accelerate. The gap between trailing and forward P/E suggests analysts anticipate a significant earnings increase, likely driven by Dupixent expansion and cost discipline. Compared to the biotechnology industry average P/E of approximately 22x (based on sector data), Regeneron's trailing P/E of 17.9x represents a 19% discount, while the forward P/E of 12.0x is a 45% discount. This discount is justified by the recent pipeline setback and slower near-term growth expectations, but it also presents a potential value opportunity if the pipeline recovers. Historically, Regeneron's trailing P/E has ranged from 4.7x (mid-2021) to 36.2x (early 2024). The current 17.9x is near the lower end of its five-year range, suggesting the stock is cheap relative to its own history. This low multiple reflects the market's skepticism about future growth, but could also indicate a buying opportunity if the company delivers on its pipeline and revenue targets.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Regeneron's net margin compressed to 20.2% in Q1 2026 from 38.9% in Q3 2025, driven by a 23% YoY increase in R&D spending to $1.645B. While the company generates strong free cash flow ($4.16B TTM), the elevated spending on pipeline programs could pressure earnings if revenue growth slows. The debt-to-equity ratio is very low at 0.087, so financial leverage is not a concern, but the high payout ratio for buybacks ($794M in Q1) could reduce financial flexibility if cash flows decline. Revenue concentration in Dupixent and Eylea, both subject to patent expirations and competition, poses a risk to long-term growth.
Market & Competitive Risks: The stock's beta of 0.236 indicates low correlation with the market, but company-specific risks dominate. The biotech sector is highly competitive, with rivals like AbbVie and Amgen advancing immunology and oncology pipelines. The Phase 3 failure in May 2026 highlights the binary nature of clinical trials, which can lead to sharp price swings. Valuation compression is a risk if the forward P/E of 12.0x expands due to negative sentiment, but the current discount to peers provides a cushion. Regulatory headwinds, such as pricing pressure on Eylea from biosimilars, could also impact revenue.
Worst-Case Scenario: If further pipeline failures occur or key products face unexpected competition, the stock could fall to its 52-week low of $541.00, representing a 17.5% decline from the current price of $656.01. In a severe scenario, if Dupixent sales disappoint or a major patent loss occurs, the stock could test the $500 level, implying a 24% downside. The historical max drawdown of 26.05% suggests that a drop to around $485 is possible in an extreme bear case, though this is less likely given the company's strong fundamentals.
FAQ
The primary risk is pipeline failure, as evidenced by the May 2026 Phase 3 setback that erased ~15% of market cap. Financial risks include margin compression, with operating margin falling to 17.8% from 27.3% in Q3 2025 due to rising R&D costs. Competitive risks include biosimilar threats to Eylea and Dupixent patent expirations. Macro risks are low given a beta of 0.236, but sector rotation away from biotech could pressure the stock. The most severe risk is a series of pipeline failures that could drive the stock to the 52-week low of $541, a 17.5% downside from current levels.
The 12-month forecast is cautiously bullish. The base case (50% probability) sees the stock reaching $700-$819, driven by steady revenue growth and margin stabilization. The bull case (25% probability) targets $819-$1,000, contingent on positive pipeline news. The bear case (25% probability) sees downside to $541-$641 if further setbacks occur. The analyst consensus is Buy with an average target of $819.25, implying 24.9% upside. The most likely scenario is the base case, assuming no major negative surprises.
Regeneron appears undervalued based on both trailing and forward P/E. The trailing P/E of 17.9x is below the biotech industry average of 22x, and the forward P/E of 12.0x implies the market expects significant earnings growth. Historically, the stock has traded at higher multiples, with a five-year range of 4.7x to 36.2x. The current low multiple reflects skepticism about pipeline prospects, but if the company delivers on growth, the stock could re-rate. The PEG ratio of 3.38 suggests it is not cheap on a growth-adjusted basis, but the strong free cash flow yield of 5.2% supports the undervaluation thesis.
Regeneron is a good buy for long-term investors seeking a high-quality biotech at a discount. The stock offers a 24.9% upside to the analyst average target of $819.25, supported by 19% revenue growth and a forward P/E of 12.0x, which is a 45% discount to the industry average. However, the recent Phase 3 failure introduces risk, and the stock is in a downtrend. For risk-tolerant investors, the current price provides an attractive entry point, but those with low risk tolerance may prefer to wait for a catalyst. The strong balance sheet and cash flows provide a safety net, making it a compelling value play.
Regeneron is best suited for long-term investment (3-5 years) due to its strong fundamentals, discounted valuation, and pipeline potential. The low beta of 0.236 indicates low market correlation, making it less suitable for short-term trading based on macro moves. The stock's volatility is driven by company-specific catalysts, which can create short-term opportunities, but the risk of binary events (e.g., trial results) makes short-term holding risky. Long-term investors can benefit from the compounding of revenue growth and share buybacks. A minimum holding period of 3 years is recommended to allow pipeline catalysts to materialize.
